INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Data sources
SEC FORM 440m ago
HOUSE PTR40m ago
SEC 13F40m ago
ROBINHOOD CHAIN40m ago
Public company

Opus Genetics, Inc.

IRDCIK 0001228627

EDGAR filingsOpen in network
Price$4.18
1 year+97.2%
Disclosed transactions4
Buys / sells0 / 4
Max Insider Score38
Connections with evidence5

IRD · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
24
MG
Magrath GeorgeDirector, Chief Executive Officer
IRDOpus Genetics, Inc.
Open-market sale
SELL$110K
28.3K sh
Nov 3, 2026Nov 5, 2026

Verified connections

  • ← Insider ofevidence
    Magrath GeorgeDirector, Chief Executive Officer · Nov 5, 2026
  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Lobbied forevidence
    JEFFREY J. KIMBELL & ASSOCIATES, INC.LDA Q2 2026 second quarter · Health issues · Aug 26, 2026
  • ← Insider ofevidence
    Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks · Dec 11, 2025
  • ← Insider ofevidence
traded Nov 3, 2026
+2d
SEC FORM 4

Evidence

30
FF
Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks
IRDOpus Genetics, Inc.
Open-market sale
SELL$2.76M
556.0K sh
Sep 30, 2026Oct 2, 2026
traded Sep 30, 2026
+2dSEC FORM 4

Evidence

34
FF
Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks
IRDOpus Genetics, Inc.
Open-market sale
SELL$7.39M
1.70M sh
May 18, 2026May 20, 2026
traded May 18, 2026
+2dSEC FORM 4

Evidence

38
FF
Foundation Fighting Blindness Retinal Degeneration FundDirector, See Remarks
IRDOpus Genetics, Inc.
Open-market sale
SELL$8.60M
4.00M sh
Dec 9, 2025Dec 11, 2025
traded Dec 9, 2025
+2dSEC FORM 4

Evidence

Foundation Fighting Blindness, Inc.
Director, See Remarks · Dec 11, 2025

Lobbying

$30K reported · de-duplicated
2026 Q2 $15K via firms2026 Q1 $15K via firms
  • JEFFREY J. KIMBELL & ASSOCIATES, INC.$15K2026 Q1 · posted Aug 26, 2026 · Health issues
  • JEFFREY J. KIMBELL & ASSOCIATES, INC.$15K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.